Neovascular (Wet) Age-Related Macular Degeneration
14
2
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
7.1%
1 terminated out of 14 trials
83.3%
-3.2% vs benchmark
14%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (14)
Effectiveness of Multidisciplinary Protocolised Interventions on IVT Non-adherence Rates
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD
The Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Degeneration
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications